ERBB2 and aneurysmal bone cyst: However, despite this dramatic improvement, approximately 20% of HER2+ aBC patients receiving dual anti-HER2 blockade undergo precocious disease progression (i.e., within 6 months after treatment initiation) as a result of primary tumor resistance [9].